Sort
16,179 grants matching “malaria”
ALABAMA/ZAMBIA HIV VACCINE CLINICAL TRIALS UNIT (HVTU)
$1,189,451University Of Alabama At Birmingham · U01 · FY2001 · AI
Computational models of naturally acquired immunity to falciparum malaria
$1,189,438Bryan R Greenhouse · University Of California, San Francisco · U01 · FY2022 · AI
Vaccine and Treatment Evaluation Unit at Saint Louis University
$1,189,190Daniel F. Hoft · Saint Louis University · UM1 · FY2024 · AI
Implementing Vaccine and Treatment Evaluation Unit (VTEU) Clinical Site
$1,188,978Karen L. Kotloff · University Of Maryland Baltimore · UM1 · FY2022 · AI
Development of an anti-malaria toxin vaccine candidate
$1,186,750William J Christ · Ancora Pharmaceuticals, Inc. · R44 · FY2007 · AI
Computational models of naturally acquired immunity to falciparum malaria
$1,183,322Bryan R Greenhouse · University Of California, San Francisco · U01 · FY2023 · AI
Optimal chemopreventive regimens to prevent malaria and improve birth outcomes in Uganda
$1,181,537Matthew G Dorsey · University Of California, San Francisco · U01 · FY2022 · AI
Vector-Borne Diseases: Biology Of Vector Host Relationship
$1,180,925Jose Ribeiro · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI
SickleGenAfrica:Sickle Cell Disease Genomics Network of Africa
$1,180,073Solomon Fiifi Ofori-Acquah · University Of Ghana · U54 · FY2017 · HL
AWI-Gen Phase 2: Genomic and environmental risk factors for cardiometabolic disease in Africans
$1,179,963Michele Michele Ramsay · Wits Health Consortium (Pty), Ltd · U54 · FY2017 · HG
Studies on Arthropod Vectors of Disease
$1,178,907Robert Gwadz · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI
Malaria Vaccine: Pfs25-Pvs25
$1,178,399Patrick Duffy · National Institute Of Allergy And Infectious Diseases · ZIA · FY2014 · AI
Computational models of naturally acquired immunity to falciparum malaria
$1,177,782Bryan R Greenhouse · University Of California, San Francisco · U01 · FY2024 · AI
RP3: Targeting ATG gene-dependent immunity for novel anti-infective therapeutics
$1,177,671Seungmin Hwang · Ut Southwestern Medical Center · U19 · FY2021 · AI
Optimal chemopreventive regimens to prevent malaria and improve birth outcomes in Uganda
$1,177,157Matthew G Dorsey · University Of California, San Francisco · U01 · FY2023 · AI
Gametocyte Carriage Rate and Transmission Blocking Vaccine Assay Development
$1,176,799Patrick Duffy · National Institute Of Allergy And Infectious Diseases · ZIA · FY2013 · AI
Research to control and eliminate malaria in SE Asia and SW Pacific
$1,175,567James Walter Kazura · Case Western Reserve University · U19 · FY2012 · AI
Evaluation of Novel PE Malaria Vaccine Candidates
$1,175,442Patrick Duffy · National Institute Of Allergy And Infectious Diseases · ZIA · FY2013 · AI
Long-term health and socioeconomic impact of interventions targeting low-density malaria infection (LMI) among children in Tanzaniav
$1,175,287Michelle Sang Hsiang · University Of California, San Francisco · U01 · FY2025 · AI
Task 3: Preclinical Services for the Development of Interventional Agents
$1,174,695Jon Carl Mirsalis · Sri International · N01 · FY2011 · AI
International Center for Excellence in Research (ICER) in Uganda: Impact of ARVs
$1,173,678Thomas Quinn · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
Epidemiology, Prevention, and Treatment of Influenza and Other Respiratory Infect
$1,172,388Dean Barry Everett · University Of Liverpool · U01 · FY2014 · IP
Center for Transformative Infectious Disease Research (CTIDR)
$1,171,164Alexander J Travis · Cornell University · P20 · FY2025 · AI
Development of MecVax, a Cross Protective Subunit Vaccine for ETEC
$1,170,694Weiping Zhang · University Of Illinois At Urbana-Champaign · R01 · FY2023 · AI
Malaria Parasite Ligands And Host Cell Receptors
$1,170,400Louis Miller · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI